1. Academic Validation
  2. Identification of indole inhibitors of human hematopoietic prostaglandin D2 synthase (hH-PGDS)

Identification of indole inhibitors of human hematopoietic prostaglandin D2 synthase (hH-PGDS)

  • Bioorg Med Chem Lett. 2015 Jun 15;25(12):2496-500. doi: 10.1016/j.bmcl.2015.04.065.
Fredrik Edfeldt 1 Johan Evenäs 2 Matti Lepistö 2 Alison Ward 2 Jens Petersen 3 Lisa Wissler 3 Mattias Rohman 3 Ulf Sivars 2 Karin Svensson 2 Matthew Perry 2 Isabella Feierberg 3 Xiao-Hong Zhou 2 Thomas Hansson 2 Frank Narjes 2
Affiliations

Affiliations

  • 1 Discovery Sciences, Innovative Medicines, AstraZeneca R&D, 431 83 Molndal, Sweden. Electronic address: Fredrik.Edfeldt@astrazeneca.com.
  • 2 Respiratory, Inflammation and Autoimmunity, Innovative Medicines, AstraZeneca R&D, 431 83 Molndal, Sweden.
  • 3 Discovery Sciences, Innovative Medicines, AstraZeneca R&D, 431 83 Molndal, Sweden.
Abstract

Human H-PGDS has shown promise as a potential target for anti-allergic and anti-inflammatory drugs. Here we describe the discovery of a novel class of indole inhibitors, identified through focused screening of 42,000 compounds and evaluated using a series of hit validation assays that included fluorescence polarization binding, 1D NMR, ITC and chromogenic enzymatic assays. Compounds with low nanomolar potency, favorable physico-chemical properties and inhibitory activity in human mast cells have been identified. In addition, our studies suggest that the active site of hH-PGDS can accommodate larger structural diversity than previously thought, such as the introduction of polar groups in the inner part of the binding pocket.

Keywords

Focused screening; Hit validation; Indole; PGDS inhibitors; Prostaglandin D(2) synthase.

Figures